SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT02575560

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

High Dose Weekly Use First-generation EGFR-TKI Instead of Daily Regular Dose in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Cancer (NSCLC)

EGFR-TKI is the main is the first line therapy for local advanced or metastatic non-small cell lung cancer with EGFR gene mutation. The median progression free survival time is around 11 months with the first generation EGFR-TKI. Patients with acquired resistance with first generation EGFR-TKI usually with EGFR exon 20 mutation (T790M). Change the drug administration maybe prolong patients PFS and evently prolong OS.

NCT02575560 EGFR-TKI Resistant Mutation
MeSH: Carcinoma, Non-Small-Cell Lung
HPO: Non-small cell lung carcinoma

1 Interventions

Name: history data

Description: history data of PFS after 1st line or second line theray

Type: Other

weekly use erolotinib vs history data


Primary Outcomes

Measure: Progression Free Survival Time (PFS)

Time: an average 1 year

Secondary Outcomes

Measure: Overall Response Rate(ORR)

Time: an average half year

Measure: Overall Survival Time (OS)

Time: an average 2 year

Time Perspective: Prospective

Case-Only


There is one SNP

SNPs


1 T790M

Patients with acquired resistance with first generation EGFR-TKI usually with EGFR exon 20 mutation (T790M). --- T790M ---

EGFR-TKI Resistant Mutation Carcinoma, Non-Small-Cell Lung 1st generation EGFR-TKI has reversible binding to EGFR, it also bind to T790M in a high dose which is account about 60% patients acquired resistance to the drug. --- T790M ---

Resistance patients may be benefit to a bolus drug use to block T790M gene. --- T790M ---



HPO Nodes


HPO:
Non-small cell lung carcinoma
Genes 3
TP53 TP53 BAP1